Could a pill and light combo beat vitiligo?
NCT ID NCT07152626
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether taking a daily pill (ritlecitinib) plus twice-weekly narrowband UVB light therapy works better than the pill alone for vitiligo. About 56 adults with non-segmental vitiligo covering 4-60% of their body will take part. The main goal is to see how much skin color returns on the face and body after 52 weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ritlecitinib (a JAK inhibitor pill) and narrowband UVB light therapy
What this could lead to
If this combination works better than the pill alone, it could offer a more effective treatment option for vitiligo, helping to restore skin color more quickly.
What could go wrong
This is a Phase 2 trial with only 56 participants, so results are still early. The added benefit of UVB may be small, and UVB requires frequent clinic visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VITILIGO are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP
RECRUITINGParis, Creteil, 94010, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU La Réunion
RECRUITINGLa Réunion, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
CHU de Bordeaux
RECRUITINGBordeaux, 33000, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHu de Nice, Hôpital Archet
RECRUITINGNice, Alpes-Maritime, 06200, France
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HCL
RECRUITINGLyon, 69000, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••